Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.
Other analysts also recently issued research reports about the company. Weiss Ratings upgraded Kailera Therapeutics from a "sell (d-)" rating to a "sell (d)" rating in a research note on Wednesday, October 21st. Canaccord Genuity Group initiated coverage on Kailera Therapeutics in a report on Monday, November 9th. They set a "buy" rating and a $44.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.
Get Our Latest Research Report on Kailera Therapeutics
Kailera Therapeutics Stock Down 4.8%
KLRA stock opened at $11.02 on Friday. Kailera Therapeutics has a 1 year low of $9.76 and a 1 year high of $28.23. The company has a fifty day simple moving average of $12.22 and a 200 day simple moving average of $17.35.
Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($1.55) by $0.81. As a group, sell-side analysts forecast that Kailera Therapeutics will post -3.71 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of KLRA. Algert Global LLC bought a new position in shares of Kailera Therapeutics in the third quarter worth about $1,008,000. Goldman Sachs Group Inc. boosted its stake in Kailera Therapeutics by 65.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 696,577 shares of the company's stock valued at $7,955,000 after purchasing an additional 275,543 shares during the period. Jump Financial LLC bought a new stake in Kailera Therapeutics during the 3rd quarter valued at approximately $4,351,000. Marshall Wace LLP acquired a new stake in Kailera Therapeutics in the 3rd quarter valued at approximately $10,029,000. Finally, State Street Corp grew its holdings in Kailera Therapeutics by 158.2% in the 3rd quarter. State Street Corp now owns 2,241,320 shares of the company's stock valued at $25,596,000 after buying an additional 1,373,160 shares during the last quarter.
About Kailera Therapeutics
(
Get Free Report)
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism. The company's pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use. Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kailera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kailera Therapeutics wasn't on the list.
While Kailera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.